ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“MAP2025: New studies identify epigenomic signatures that could prove useful to overcome different challenges in oncology.
In glioma, analyses suggest that blood DNA methylation profiles reflecting molecular changes in muscle tissue could help in the prediction of cachexia.
In high-grade serous Ovarian Cancer, epigenomic changes after Neoadjuvant Chemotherapy could shed light on biomarkers of response, leading to more Personalised Medicine.
Learn more in the ESMO Daily Reporter.”
More Posts Featuring ESMO.